One company this week got a different verdict from the other three.
AbbVie came back Clear for Deeper Research. Here is what the Firewall found.
The story: AbbVie has engineered one of the most impressive patent-cliff recoveries in pharmaceutical history. Skyrizi and Rinvoq are growing fast enough to replace Humira revenue as biosimilar competition erodes the former blockbuster. The combined portfolio across immunology, oncology, neuroscience, and aesthetics frames AbbVie as a company that has already recovered rather than one still in transition.
The hidden assumption:
“Investors currently believe that Skyrizi and Rinvoq’s combined revenue trajectory is growing fast enough and with sufficient pricing durability to fully absorb Humira’s ongoing biosimilar erosion and sustain AbbVie’s earnings and dividend growth.”
Clear for Deeper Research means the filing evidence is directionally supportive. Q1 2026 showed Skyrizi at $3.4 billion, up 49 percent year over year. Rinvoq at $1.5 billion, up 50 percent. The revenue math is working.
The open question is whether the margin math is keeping pace. Humira carried gross margins above 85 percent historically. If the replacement drugs carry 75 to 80 percent, every dollar of revenue replaced comes with a margin gap. At this scale that gap compounds.
Immunology segment gross margin in the Q1 10-Q is the specific number to find.
Run ABBV: longview-firewall.netlify.app